Fierce Biotech April 26, 2024
A three-year collaboration between Pfizer and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) has resulted in a new AI-driven drug discovery method that could make it faster and easier to identify small molecules with therapeutic potential.
In an article published April 25 in Science, CeMM researchers described how they created and scaled an AI and machine learning platform that measures how hundreds of small molecules bind to thousands of different human proteins, generating a catalog that can be used as the starting point for new drug development. The models used and all data from them are available for free to other researchers in the form of a web application, according to a press...
Today's Sponsors
Today's Sponsor